Goserelin Dosing & Reconstitution Guide
Dosing Protocol
Route: Subcutaneous implant (anterior abdominal wall) Frequency: Every 28 days (3.6 mg) or every 12 weeks (10.8 mg) Dose Range: Prostate cancer: 3.6 mg q28d or 10.8 mg q12w. Breast cancer: 3.6 mg q28d. Endometriosis: 3.6 mg q28d for 6 months.
Timeline & Pharmacokinetics
Onset: 2-4 weeks (hormonal suppression) Half-Life: ~4.2 hours Steady State: 2-4 weeks Time to Results: 2-4 weeks for castrate testosterone levels Washout: 4-12 weeks depending on implant
Storage
Lyophilized: Store below 25 °C (77 °F); do not freeze Reconstituted: Not applicable (pre-filled syringe/implant)
Safety & Contraindications
Safety: Hot flashes (up to 57-75% of patients) Decreased bone mineral density with prolonged use Initial disease flare (1-2 weeks): tumor flare in prostate cancer with potential spinal cord compression, bone pain exacerbation
Contraindications: Pregnancy (Category X/D depending on indication); Undiagnosed vaginal bleeding; Hypersensitivity to GnRH, GnRH agonist analogs, or PLGA